Today: 7 February 2026
Subscribe
Browse Category

NYSE:LLY News 30 December 2025 - 5 January 2026

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

New York, January 5, 2026, 10:58 (ET) — Regular session Eli Lilly and Company shares fell about 3.4% on Monday, extending early losses after rival Novo Nordisk began selling a pill version of its Wegovy weight-loss drug in the United States. The stock was down at $1,043.14 after dipping nearly 4% earlier in the session. The move puts the spotlight back on pricing power in obesity drugs, a market that has helped lift Lilly’s valuation and that investors treat as a multi-year growth engine. Novo said its once-daily Wegovy pill will start at $149 a month for self-paying patients, with
5 January 2026
·····
Eli Lilly stock: What to watch before Monday as JPM Healthcare and earnings near

Eli Lilly stock: What to watch before Monday as JPM Healthcare and earnings near

NEW YORK, Jan 4, 2026, 17:22 ET — Market closed Eli Lilly shares rose 0.5% to $1,080.36 at Friday’s close, leaving the stock near the top of its recent range as U.S. markets remained shut over the weekend. Lilly Investor Relations The next catalysts are close. Investors start the week positioning for the J.P. Morgan Healthcare Conference, the industry’s first major investor gathering of the year, where management teams often set the tone for guidance and pipeline priorities. JPMorgan Chase For Lilly, the bar is higher than most. The stock’s run has been powered by demand for its obesity and
4 January 2026
·····
Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings

Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings

NEW YORK, Jan 4, 2026, 10:17 ET — Market closed Eli Lilly and Co shares ended Friday up $5.44, or 0.5%, at $1,080.36, giving the drugmaker a firm start to 2026 as investors positioned for a packed run of healthcare catalysts in January and February. The move matters because Lilly is one of the market’s largest “growth” stocks — companies whose valuations lean heavily on future earnings — and traders are resetting positions after a year in which weight-loss drugs drove outsized gains across big pharma. Investing It also comes as Washington’s push to widen access to obesity drugs moves
4 January 2026
·····
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

NEW YORK, Jan 3, 2026, 13:21 ET — Market closed Drugmakers are lifting U.S. list prices on hundreds of medicines as 2026 begins, putting drug-pricing politics back in focus for healthcare investors. The sector finished higher in Friday’s session, the last U.S. trading day before the weekend. Drugmakers plan to raise U.S. prices on at least 350 branded medicines for 2026, including vaccines for COVID-19, RSV and shingles, as well as Pfizer’s cancer drug Ibrance, Reuters reported, citing data from healthcare research firm 3 Axis Advisors. The median list-price increase is about 4%, and the changes do not reflect rebates
3 January 2026
·······
Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

NEW YORK, January 3, 2026, 10:33 ET — Market closed Eli Lilly and Company shares closed up 0.53% at $1,080.36 on Friday and were down 0.17% in after-hours trading at $1,078.50. The move matters because early January is when many drugmakers reset “list prices” — the published prices before rebates and insurer discounts — and those changes can shape negotiations with payers. Policy pressure on drug costs has also intensified as the new year begins. For Lilly, pricing headlines can carry outsized weight. The company’s growth narrative is closely tied to high-demand diabetes and obesity medicines, leaving investors sensitive to
3 January 2026
·····
Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

NEW YORK, Jan 2, 2026, 18:12 ET — After-hours Shares of Eli Lilly and Company rose about 0.5% in after-hours trading on Friday, last at $1,080.36. The stock swung between $1,052.96 and $1,080.49 during the regular session. The timing matters for drugmakers because early January is when many companies reset list prices — the sticker prices before rebates and discounts. Data from healthcare research firm 3 Axis Advisors showed manufacturers planned hikes on at least 350 branded medicines for 2026, with the median list-price increase around 4%, even as the Trump administration presses the industry for cuts. Reuters For Lilly,
3 January 2026
·····
Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

NEW YORK, January 1, 2026, 17:27 ET Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, according to data from healthcare research firm 3 Axis Advisors. The median increase is about 4%, and the figures do not reflect rebates or other discounts. The same dataset showed drugmakers also plan to cut list prices on about nine medicines, including a more than 40% reduction for diabetes drug Jardiance, sold by Boehringer Ingelheim and Eli Lilly, after Medicare negotiated a lower price for 2026. Reuters For investors, that is the opening backdrop for the Eli Lilly
1 January 2026
····
Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus

Eli Lilly stock ends 2025 lower as 2026 drug-price shifts and GLP-1 pill race come into focus

NEW YORK, January 1, 2026, 10:21 ET — Market closed Eli Lilly shares slipped 0.5% in Wednesday’s final session of 2025, closing at $1,074.68, before U.S. markets shut for the New Year’s Day holiday. StockAnalysis+1 Why it matters now: drugmakers typically reset U.S. list prices at the start of the year, and new data have put the industry’s pricing playbook back under a political microscope. Reuters reported drugmakers plan to raise list prices on at least 350 branded medicines in 2026, even as they cut prices on a handful of drugs. Reuters Lilly sits at the center of two investor
1 January 2026
····
Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

NEW YORK, December 31, 2025, 17:16 ET — After-hours Eli Lilly and Co (LLY) shares slipped in after-hours trading on Wednesday. The stock was down about 0.5% at $1,074.68, after trading between $1,074.39 and $1,083.25 during the day on roughly 1.5 million shares. Drug pricing has moved back to the center of the investment case for large-cap pharmaceuticals as Washington pushes for lower costs and companies adjust prices in overseas growth markets. For Lilly, price assumptions matter because investors have priced in years of strong growth from its GLP‑1 franchise, a hormone-based drug class used for diabetes and weight loss.
31 December 2025
····
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

NEW YORK, December 31, 2025, 13:48 ET — Regular session Eli Lilly shares edged lower on Wednesday as investors weighed new signals that blockbuster diabetes and obesity drugs are heading into 2026 with lower price tags in some markets. The stock was down 0.1% at $1,078.95 by 1:48 p.m. ET, after trading between $1,076.86 and $1,083.25. The pricing debate matters for Lilly because its growth story is dominated by GLP-1 drugs, a class of diabetes and obesity treatments that mimic a gut hormone to curb appetite and lower blood sugar. Moves that broaden access can lift volumes, but price cuts
31 December 2025
·····
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

NEW YORK, December 31, 2025, 05:39 ET — Premarket Shares of Hims & Hers Health Inc (HIMS) fell 0.5% to $32.87 in premarket trading on Wednesday after closing down 3.1% at $33.04 in the prior session. The stock has traded between $23.97 and $72.98 over the past 52 weeks. Google The drift lower keeps attention on the telehealth group’s exposure to the fast-moving market for GLP-1 weight-loss drugs — a category that has become a major battleground for pricing, access and consumer demand. That matters now because GLP-1 drugs, a class of diabetes and obesity medicines that reduce appetite, are
31 December 2025
·······
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

NEW YORK, December 30, 2025, 5:08 PM ET — After-hours Eli Lilly shares were up 0.1% in after-hours trading on Tuesday at $1,079.75 after a Reuters report said it and Novo Nordisk are lowering prices of their top-selling obesity drugs in China. Reuters The pricing move matters because investors have treated Lilly’s obesity franchise as a main growth engine, helping support a premium valuation. A sharper-than-expected push to discount in large markets can pressure margins, even if it expands the customer base. It also lands as drugmakers pivot toward cash-pay channels — patients paying out of pocket, rather than relying
30 December 2025
····
1 … 6 7 8 9 10 … 13

Stock Market Today

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

7 February 2026
Walmart shares rose 3.3% Friday to $131.18, up 10% since Jan. 30, as the Dow closed above 50,000 for the first time. The retailer’s market value crossed $1 trillion this week. Investors await January inflation data on Feb. 13 and Walmart’s quarterly results on Feb. 19 for signs of continued momentum.
Go toTop